Download
https://www.ndtvprofit.com/research-reports/alembic-pharma-margins-to-remain-under-pressure-nirmal-bang?utm_source=telegram&utm_medium=referral&utm_campaign=socialshare
Despite aggressive spends on capex and R&D for the U.S. market, we do not see any meaningful visible large launches.
Share